

July 30, 2021

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai — 400 001.

Sub: Outcome of the Board Meeting Dated 30th July, 2021.
Scrip Code: 524774

Dear Sir/Madam,

This is to inform you that the Second Meeting of the Board of Directors of NGL Fine-Chem Limited for the Financial Year 2021-2022 held on Friday, 30th July, 2021 at 301 E-Square, Subhash Road, Vile Parle East, Mumbai 400057 approved the following:

Approved Unaudited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We further enclose herewith the Limited Review Report on Standalone and Consolidated Financial Results issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at www.nglfinechem.com.

The meeting of the Board of Directors commenced at 5.00 p.m. and concluded at 5.50 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited



Pallavi Pednekar
Company Secretary & Compliance Officer
Membership No: A33498





MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110
2618 5137
shailesh.manek@gmail.com
shailesh@camanek.com
www.camanek.com

SHAILESH MANEK
B.Com.(Hons), Grad. C.W.A.,F.C.A.
Cell: +91 93222 26311

MITTUL DALAL
B.Com. A.C.A
Cell: +91 80973 74277

Review report to
The Board of Directors,
M/s.NGL Fine-Chem Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s.NGL Fine-Chem Limited** for the period ended **June 30, 2021**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**
Chartered Accountants
Firm's Registration No.:**126679W**



SLR Manek
(SHAILESH MANEK)

Partner

Membership Number:**034925**

UDIN: **21034925AAAAJJ6735**

MUMBAI

Dated: **30/07/2021**



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

2618 5137

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

Cell: +91 93222 26311

MITTUL DALAL

B.Com. A.C.A

Cell : +91 80973 74277

Independent Auditor's Review Report

To,
The Board of Directors,
M/s.NGL Fine-Chem Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s.NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/s.Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended **30th June 2021** and for the period from **01st April 2021 to 30th June 2021** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s.Macrotech Polychem Private Limited, its wholly owned subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**
Chartered Accountants
Firm's Registration No.: **126679W**



MUMBAI
Dated : **30/07/2021**


(SHAILESH MANEK)
Partner

Membership Number: **034925**
UDIN: **21034925AAAAJL9717**

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2021

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2021

| | Particulars | Quarter ended | | Year ended | |
|-------|---|---------------------------|-------------------------|---------------------------|-------------------------|
| | | 31.03.2021 | | 31.03.2021 | |
| | | 30.06.2021 (Unaudited) | 31.03.2021 (Audited) | 30.06.2020 (Unaudited) | 31.03.2021 (Audited) |
| I | Revenue from Operations | 7,586.28 | 7,177.17 | 4,236.83 | 25,797.48 |
| II | Other Income | 455.05 | 229.79 | 218.30 | 801.75 |
| III | Total Revenue (I+II) | 8,041.33 | 7,406.96 | 4,455.13 | 26,599.23 |
| IV | Expenses : | | | | |
| | a) Cost of Material Consumed | 3,433.30 | 2,087.48 | 1,769.88 | 10,048.25 |
| | b) (Increase)/Decrease in stock in trade and work in progress | (207.68) | 567.28 | (79.70) | 186.12 |
| | c) Employee benefits expenses | 746.10 | 741.45 | 539.89 | 2,809.28 |
| | d) Finance Costs | 37.01 | 32.71 | 60.22 | 184.01 |
| | e) Depreciation and amortisation expenses | 217.81 | 207.99 | 209.62 | 833.40 |
| | f) Other expenses | 1,257.89 | 1,702.08 | 662.10 | 4,779.21 |
| | Total Expenses (IV) | 5,484.43 | 5,338.99 | 3,162.01 | 18,840.27 |
| V | Profit/(loss) before exceptional items and tax (III-IV) | 2,556.90 | 2,067.97 | 1,293.12 | 7,758.95 |
| VI | Exceptional Items | - | - | - | - |
| VII | Profit/(loss) Before Tax (V-VI) | 2,556.90 | 2,067.97 | 1,293.12 | 7,758.95 |
| VIII | Tax Expense | | | | |
| | a) Current Tax | (605.50) | (662.40) | (288.30) | (1,943.00) |
| | b) MAT Tax | - | - | - | (0.33) |
| | c) Prior Years | - | (1.82) | - | (143.72) |
| | d) Deferred Tax | (38.82) | (19.83) | (66.10) | (143.72) |
| IX | Profit/ (Loss) for the period from continuing operations (VII-VIII) | 1,912.58 | 1,383.92 | 938.72 | 5,671.89 |
| X | Other Comprehensive Income | | | | |
| | a. Gain/(Loss) on actuarial valuation of post employment benefits | 2.10 | 9.92 | (4.64) | (18.82) |
| | b. Deferred tax on above | (0.53) | (2.49) | 1.17 | 4.74 |
| | c. Other Comprehensive Income (Net of Tax) | 1.57 | 7.43 | (3.47) | (14.08) |
| XI | Total Comprehensive Income | 1,914.15 | 1,391.35 | 935.25 | 5,657.81 |
| XII | Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each) | 308.90 | 308.90 | 308.90 | 308.90 |
| XXIII | Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year | N.A | N.A | N.A | 15,136.88 |
| XIV | Earnings Per Share (EPS) | | | | |
| | a) Basic | ₹ 30.96 | ₹ 22.40 | ₹ 15.19 | ₹ 91.81 |
| | b) Diluted | ₹ 30.96 | ₹ 22.40 | ₹ 15.19 | ₹ 91.81 |
| | Particulars | Quarter ended | | Year ended | |
| | | 31.03.2021 | | 31.03.2021 | |
| | | 30.06.2021 (Unaudited) | 31.03.2021 (Audited) | 30.06.2020 (Unaudited) | 31.03.2021 (Audited) |
| I | Revenue from Operations | 7,590.88 | 7,178.88 | 4,242.36 | 25,520.76 |
| II | Other Income | 492.23 | 253.48 | 225.36 | 1,152.09 |
| III | Total Revenue (I+II) | 8,083.11 | 7,432.36 | 4,467.72 | 26,672.85 |
| IV | Expenses : | | | | |
| | a) Cost of Material Consumed | 3,411.25 | 2,064.43 | 1,772.00 | 10,063.96 |
| | b) (Increase)/Decrease in stock in trade and work in progress | (207.68) | 567.28 | (79.70) | 186.12 |
| | c) Employee benefits expenses | 718.92 | 715.64 | 528.20 | 2,723.50 |
| | d) Finance Costs | 37.01 | 32.71 | 60.21 | 184.01 |
| | e) Depreciation and amortisation expenses | 193.34 | 185.15 | 186.67 | 739.40 |
| | f) Other expenses | 1,355.71 | 1,749.62 | 760.58 | 5,176.15 |
| | Total Expenses (IV) | 5,508.55 | 5,314.83 | 3,227.96 | 19,073.14 |
| V | Profit/(loss) before exceptional items and tax (III-IV) | 2,574.56 | 2,117.53 | 1,239.76 | 7,599.71 |
| VI | Exceptional Items | - | - | - | - |
| VII | Profit/(loss) Before Tax (V-VI) | 2,574.56 | 2,117.53 | 1,239.76 | 7,599.71 |
| VIII | Tax Expense | | | | |
| | a) Current Tax | (600.00) | (666.00) | (285.00) | (1,912.00) |
| | b) MAT Tax | - | - | - | 5.05 |
| | c) Prior Years | - | - | - | (145.80) |
| | d) Deferred Tax | (39.69) | (20.75) | (67.39) | (145.80) |
| IX | Profit/ (Loss) for the period from continuing operations (VII-VIII) | 1,934.87 | 1,430.78 | 887.37 | 5,546.96 |
| X | Other Comprehensive Income | | | | |
| | a. Gain/(Loss) on actuarial valuation of post employment benefits | 2.12 | 9.94 | (4.61) | (18.81) |
| | b. Deferred tax on above | (0.54) | (2.50) | 1.16 | 4.73 |
| | c. Other Comprehensive Income (Net of Tax) | 1.58 | 7.44 | (3.45) | (14.08) |
| XI | Total Comprehensive Income | 1,936.45 | 1,438.22 | 883.92 | 5,532.88 |
| XII | Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each) | 308.90 | 308.90 | 308.90 | 308.90 |
| XXIII | Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year | N.A | N.A | N.A | 15,236.36 |
| XIV | Earnings Per Share (EPS) | | | | |
| | a) Basic | ₹ 31.32 | ₹ 23.16 | ₹ 14.36 | ₹ 89.79 |
| | b) Diluted | ₹ 31.32 | ₹ 23.16 | ₹ 14.36 | ₹ 89.79 |

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 30th July, 2021. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrochem Polychem Private Limited. Previous period figures have been regrouped/rearranged wherever necessary.
- Previous period figures have been regrouped/rearranged wherever necessary.

Rahul Nechane
 For and On behalf of Board of Directors
 Managing Director
 DIN 00223346